Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

for heart failure and need for repeat vascularization. Strikingly, this analysis found a significant association between injected cell volume and improvement in ejection fraction that is suggestive of a dose effect. This summation of prior studies supports Amorcyte's subsequent prospective findings.

"Having successfully confirmed a dose effect, Amorcyte looks forward to proceeding with a larger prospective randomized trial and furthering our clinical program with AMR-001," said Andrew Pecora, M.D., Chairman of the Board of Amorcyte. "These strong Phase I results, combined with proprietary innovative technologies that address the challenges of commercializing stem cell products, position us to bring to market a stem cell therapy with the potential to address a serious unmet patient need."

About Cardiovascular Disease

It is estimated that each year there are approximately 1.1 million instances of acute myocardial infarction (AMI). 160,000 AMIs are severe enough to cause ventricular remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling.

About Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and ot
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") ... today announces that application has been sought for 530,000 new ... admitted to trading on AIM. The new Ordinary Shares are ... Philip Haworth, former Chief Executive Officer of Silence. ...
... WEST LAFAYETTE, Ind. ╨ Engineers have discovered details about ... new applications in manufacturing, diagnostics and other research., ... create features and surface textures in metals, ceramics and other ... biosensors. The lasers pulse at durations of 100 femtoseconds, or ...
... CAMBRIDGE, Mass., Dec. 19, 2011 Access Industries ... a new life sciences venture investment initiative to ... team,s experience in startup creation, technology commercialization and ... and also create de-novo spinoffs around potential high-impact ...
Cached Biology Technology:Silence Therapeutics Additional Listing 2Silence Therapeutics Additional Listing 3Research could improve laser-manufacturing technique 2Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities 2Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities 3
(Date:4/15/2014)... of Arts and Sciences (KNAW) has announced the names ... prestigious Heineken Prizes (one million US dollars prize money ... their great merits to science. , This year marks ... to the Austrian-American chemist Erwin Chargaff in 1964. , ... to the following laureates: , Christopher M. ...
(Date:4/15/2014)... soon could be powering the forklifts used in warehouses ... faster refueling times than ever before, courtesy of a ... (HHC). , The goal of the project is to ... at low pressure four to five times faster than ... a competitive advantage over batteries for a big slice ...
(Date:4/14/2014)... to unravel the molecular changes that underlie one of ... When the bacterium Yersinia pestis enters the lungs, it ... fatal if untreated. The way in which Y. ... in a matter of days has largely confounded scientists, ... the presence of a protein called the plasminogen activator ...
Breaking Biology News(10 mins):Five scientists awarded prestigious Heineken Prizes 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4Plague alters cell death to kill host 2
... Iceland,s Eyjafjallajoekull volcano have produced a 1600 km-wide ash ... and then south, is clearly visible in stark contrast ... May. The volcano began emitting steam and ash ... month. Renewed activity earlier this week caused some flights ...
... Assistant Professor Carla Finkielstein has been presented with a ... by the American Association for Cancer Research (AACR), is ... researchers and increase the recognition of minorities involved in ... in the Department of Biological Sciences in the College ...
... a leading scientist at the Office of Naval Research, discussed ... and wastewater during National Public Radio,s recent "Science Friday" segment. ... of the microbial fuel cell to power different types of ... program officer for ONR,s Naval Biosciences and Biocentric Technology Program. ...
Cached Biology News:Biologist Carla Finkielstein receives Minority Scholar Award 2ONR scientist generates 'mud power' for NPR radio audience 2
... is the universal bioinformatics software that has ... The unique modular design of BioNumerics allows ... any type of data employed for the ... DNA fingerprints, 2-D protein gels, HPLC, VNTR, ...
Request Info...
Cultrex 3D Culture Matrix Rat Collagen I....
Cultrex 3D Culture Matrix BME....
Biology Products: